Observational studyBritish journal of clinical pharmacology2014
β-Adrenoceptor blockers and pulmonary function in the general population: the Rotterdam Study.
Observational study in British journal of clinical pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison.Respiratory research · 2021Pooled it
- Chronic β-Blockade and Systemic Homeostasis: Molecular Integration of Cardiorenal and Immune Pathways, a Narrative Review.Biomolecules · 2025Review
- Pericarpium Trichosanthis Injection Protects Isoproterenol-Induced Acute Myocardial Ischemia via Suppressing Inflammatory Damage and Apoptosis Pathways.Biomolecules · 2025Article
- Sodium channel blockers as add-on treatment for unexplained refractory chronic cough: a case report and review.Frontiers in medicine · 2025Article
- Review
- Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences.Therapeutic advances in chronic disease · 2023Review
- Optimal Management of Heart Failure and Chronic Obstructive Pulmonary Disease: Clinical Challenges.International journal of general medicine · 2022Review
- Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of randomized controlled trials.Scientific reports · 2021Article
- The Association Between β-Blocker Use and Cardiorespiratory Fitness: The Maastricht Study.Journal of cardiovascular pharmacology and therapeutics · 2019Observational
- Considerations of prescribers and pharmacists for the use of non-selective β-blockers in asthma and COPD patients: An explorative study.Journal of evaluation in clinical practice · 2018Observational
- Comparison of Long-Term Clinical Implications of Beta-Blockade in Patients With Obstructive Airway Diseases Exposed to Beta-Blockers With Different β1-Adrenoreceptor Selectivity: An Italian Population-Based Cohort Study.Frontiers in pharmacology · 2018Article
- Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease.Heart failure reviews · 2017Review
- Paradigms in chronic obstructive pulmonary disease: phenotypes, immunobiology, and therapy with a focus on vascular disease.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2017Review
- Novel selective βFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017Article
- βScientific reports · 2017Article
- Long-term effects of beta-blocker use on lung function in Japanese patients with chronic obstructive pulmonary disease.International journal of chronic obstructive pulmonary disease · 2017Article
- Obstructive Ventilatory Disorder in Heart Failure-Caused by the Heart or the Lung?Current heart failure reports · 2016Review
- Pharmacological Management of Elderly Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome: Room for Speculation?Drugs & aging · 2016Review
- The Rotterdam Study: 2016 objectives and design update.European journal of epidemiology · 2015Article
- Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease.International journal of chronic obstructive pulmonary disease · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimβ-Adrenoceptor blockers have been used with caution in patients with obstructive lung diseases such as asthma or chronic obstructive pulmonary disease (COPD), due to the potentially increased airway reactivity and risk of bronchial obstruction. Cardioselective β-adrenoceptor blockers have a more beneficial profile than non-cardioselective β-adrenoceptor blockers and can be safely prescribed to patients with both cardiovascular disease and COPD. We hypothesized that cardioselective β-adrenoceptor blockers also affect pulmonary function.
methodsThis study was performed within the Rotterdam Study, a prospective population-based cohort study. Effects of cardioselective and non-cardioselective β-adrenoceptor blockers on pulmonary function were analysed using regression techniques with multivariable adjustment for potential confounders.
resultsCurrent use of non-cardioselective β-adrenoceptor blockers was significantly associated with a lower forced expiratory volume in 1 s (FEV1) of -198 ml (95% CI -301, -96), with a lower forced vital capacity (FVC) of -223 ml (95% CI -367, -79) and with a decreased FEV1 : FVC of -1.38% (95% CI -2.74, -0.13%). Current use of cardioselective β-adrenoceptor blockers was significantly associated with a lower FEV1 of -118 ml (95% CI -157, -78) and with a lower FVC of -167 ml (95% CI -222, -111), but did not affect FEV1: FVC. After exclusion of patients with COPD, asthma and heart failure the effects of cardioselective β-adrenoceptor blockers remained significant for FEV1 (-142 ml [95% CI -189, -96]) and for FVC (-176 ml [95% CI -236, -117]).
conclusionIn our study both non-cardioselective and cardioselective β-adrenoceptor blockers had a clinically relevant effect on both FEV1 and FVC. In contrast to cardioselective β-adrenoceptor blockers, use of non-cardioselective β-adrenoceptor blockers was associated with a significantly lower FEV1: FVC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.